CDK2 degrader 7
Based on 1 Customer Validation
CDK2 degrader 7 is an orally active CDK2 degrader, with DC50 values of 13 nM (MKN1cells) and 17 nM (TOV21G cells). CDK2 degrader 7 induces G1 phase arrest in MKN1 cells. CDK2 degrader 7 achieves tumor stasis in HCC1569 (CCNE1-amplified) xenograft models. CDK2 degrader 7 can be used for the study of CCNE1-amplified cancers.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.51%
- CAS 番号: 3030279-55-8
- 分子式: C39H46F6N8O5S
- 分子量:852.89
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
CDK2 13 nM (DC50, MKN1cells) |
CDK2 17 nM (DC50, TOV21G cells) |
CDK1 2130 nM (DC50) |
CDK2 degrader 7 (Compound 37) exhibits potent CDK2 degradation activity in MKN1 (CCNE1-amplified) and TOV21G (CCNE1-nonamplified) cells, with DC50 values of 13 nM and 17 nM[1].
CDK2 degrader 7 displays potent antiproliferative activity against MKN1 (CCNE1-amplified) cells with an IC50 of 9 nM, while showing weak activity against TOV21G (CCNE1-nonamplified) cells with an IC50 of 5760 nM[1].
CDK2 degrader 7 (4.88-5000 nM , 72 h) induces maximum G1 phase arrest (on-target effect) at 78 nM and shows off-target G2/M accumulation at 2500 nM in MKN1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | CL | Vss | T1/2 | Tmax | Cmax | AUClast | F |
|---|---|---|---|---|---|---|---|---|---|
| Dog[1] | 0.1 mg/kg | i.v. | 0.1 mL/min/kg | 3.9 L/kg | 14.4 h | / | / | / | / |
| Dog[1] | 1 mg/kg | p.o. | / | / | / | 4.0 h | 0.025 μM | 0.557 μM·h | 12 % |
| Monkey[1] | 0.07 mg/kg | i.v. | 9.1 mL/min/kg | 5.7 L/kg | 6.7 h | / | / | / | / |
| Monkey[1] | 1 mg/kg | p.o. | / | / | / | 4.0 h | 0.014 μM | 3.63 μM·h | 21 % |
| Rat[1] | 10 mg/kg | p.o. | / | / | / | 2.0 h | 0.261 μM | 3.63 μM·h | 21 % |
| Rat[1] | 2 mg/kg | i.v. | 10 mL/min/kg | 5 L/kg | 6.7 h | / | / | / | / |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HCC1569 human breast carcinoma cells (6 × 106 cells + Matrigel in 0.2 mL RPMI 1640 medium) were subcutaneously implanted into the central right flank of 7-day acclimated female NOG mice[1]
-
Dosage:10 mg/kg, 25 mg/kg, 50 mg/kg
-
Administration:p.o., once or twice daily, 28 days
-
Result:Achieved tumor stasis in HCC1569 (CCNE1-amplified) xenograft model.
化学情報
-
CAS 番号 3030279-55-8
-
性状 Solid
-
分子量 852.89
-
分子式 C39H46F6N8O5S
-
Color White to off-white
-
SMILES
O=S(C1=CC=C(NC2=NC=C(C(F)(F)F)C(N3C[C@@](C)(O)CCC3)=N2)C(F)=C1)(N[C@H]4[C@@H](F)CN(CC5CCN(C6=CC=C(C(CC7)C(NC7=O)=O)C=C6F)CC5)CC4)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 100 mg/mL (117.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1725 mL | 5.8624 mL | 11.7248 mL | 29.3121 mL |
| 5 mM | 0.2345 mL | 1.1725 mL | 2.3450 mL | 5.8624 mL | |
| 10 mM | 0.1172 mL | 0.5862 mL | 1.1725 mL | 2.9312 mL | |
| 15 mM | 0.0782 mL | 0.3908 mL | 0.7817 mL | 1.9541 mL | |
| 20 mM | 0.0586 mL | 0.2931 mL | 0.5862 mL | 1.4656 mL | |
| 25 mM | 0.0469 mL | 0.2345 mL | 0.4690 mL | 1.1725 mL | |
| 30 mM | 0.0391 mL | 0.1954 mL | 0.3908 mL | 0.9771 mL | |
| 40 mM | 0.0293 mL | 0.1466 mL | 0.2931 mL | 0.7328 mL | |
| 50 mM | 0.0234 mL | 0.1172 mL | 0.2345 mL | 0.5862 mL | |
| 60 mM | 0.0195 mL | 0.0977 mL | 0.1954 mL | 0.4885 mL | |
| 80 mM | 0.0147 mL | 0.0733 mL | 0.1466 mL | 0.3664 mL | |
| 100 mM | 0.0117 mL | 0.0586 mL | 0.1172 mL | 0.2931 mL |
CDK2 degrader 7 関連分類
HY-175842 関連分類
Powered by Bioz